Abstract
The polyene antibiotic roseofungin (registration number RK-LS-5No23224) is a new drug substance developed by the Kazakh scientists, on the basis of which the antifungal dosage form "Roseofungin-AS, ointment 2%" (registration number RK-LS-5№023225) was prepared for external application. In order to prepare a new dosage form for the treatment of vaginal candidiasis, activity of the antibiotic roseofungin was examined by the agar diffusion technique against 15 clinical fungal strains of the genus Candida: Candida albicans (9 strains), Candida krusei (2 strains), Candida tropicalis (2 strains), Candida glabrata (1 strain), Candida parapsilosis (1 strain). The antibiotic roseofungin exhibited high antifungal activity against clinical pathogens of vaginal candidiasis, the minimum inhibitory concentration varied in the range of 1.66-2.5 μg/mL. The highest activity of the antibiotic roseofungin was observed against clinical Candida albicans strains, MIC values were within the 1.66-2.0 μg/L range. Activity against Candida non-albicans strains was lower: MIC for Candida tropicalis was of 2.0 μg/mL, for Candida krusei, Candida glabrat, and Candida parapsilosis of 2.5 μg/mL. The presence of high activity in the antibiotic roseofungin against clinical pathogens of candidiasis indicates the possibility of developing new drugs on its basis that can improve the condition of patients in Kazakhstan and beyond.